SPDR S&P Biotech ETF
XBI · etf · 3 prediction records
Publication markers · exact horizontal time
P1 Prediction published1 Headline publishedP1 entry priceGraph badges open evidence. Timeline items jump to matching cards.
Chart readoutP1 is BULLISH ↑. Visible result record: NO IMMUTABLE ROW VERDICT · GRAPH SNAPSHOT. 3 of 3 timed publication events are placed from left to right.
Latest public price · never a ledger grade- Last public price
- Loading public price data…
- From P1 entry
- Entry 157.41 USD
- Latest call
- BULLISH ↑
- Publication markers
- 3 of 3 timed
Publication timelineOldest → newest
Left to right matches the graph. Select an event to jump to its full card.
- P3Prediction P3 · 11 Aug 2026, 10:17 SGTBULLISH prediction158.03 USD · NO IMMUTABLE ROW VERDICT · GRAPH SNAPSHOT
- P2Prediction P2 · 14 Aug 2026, 09:32 SGTBULLISH prediction156.86 USD · PROOF RECEIPT · HIT (NOT FOUNDER-STAMPED)
- P1Prediction P1 · 15 Aug 2026, 12:19 SGTBULLISH prediction157.41 USD · NO IMMUTABLE ROW VERDICT · GRAPH SNAPSHOT
Latest prediction · P1
-
P1
BULLISH · 157.41 USDNO IMMUTABLE ROW VERDICT · GRAPH SNAPSHOT - Published
- Deadline
Headlines · 0 · oldest first
- No eligible linked headline exists in retained publication evidence for this investible. OTR does not invent an asset match or chart time, so there is no numbered headline marker yet.
Prediction history · 2 earlier · newest first
-
P2
BULLISH · 156.86 USDPROOF RECEIPT · HIT (NOT FOUNDER-STAMPED) - Published
- Deadline
-
P3
BULLISH · 158.03 USDNO IMMUTABLE ROW VERDICT · GRAPH SNAPSHOT - Published
- Deadline
Graph LearningHow news has moved SPDR S&P Biotech ETF beforeOpen the complete asset-specific memory
OTR GRAPH LEARNING
An extra check. It does not replace the other evidence.What OTR sees for SPDR S&P Biotech ETF
What this is: An ETF tracking an equal-weighted-style basket of U.S. biotechnology companies, including many smaller firms whose value depends heavily on clinical, regulatory, and financing milestones.
Headlines that may cause the price of this investible to go up
- FDA approvals, positive pivotal-trial results, or clinical holds lifted for meaningful portfolio holdings.
- Acquisitions, licensing deals, or partnerships with credible economics and upfront funding.
- Successful financing that extends cash runway without severe dilution.
Headlines that may cause the price of this investible to go down
- Failed trials, safety signals, FDA complete-response letters, or new clinical holds.
- Dilutive equity offerings, short cash runway, restructuring, or programme discontinuation.
- Drug-pricing, reimbursement, or regulatory changes that reduce expected commercial value.
What OTR checks
- XBI daily holdings and equal-weight rebalance dates
- FDA approval calendar, complete-response letters, and clinical holds
- Clinical-trial registry status and company-reported primary endpoints
- Cash, quarterly burn, debt, shelf registrations, and expected runway
0 saved news time checks0 completed0 rose0 fell0 roughly flat
No asset-specific news signal is stored yet.
No linked headline sentiment memory is available for this investible yet. OTR shows the gap instead of guessing.
Open the full Graph Learning analysis
- Past
- 0 saved story relationships, 0 eligible measured windows. New story bindings add no measured outcome.
- Now
- News that may help includes FDA approvals, positive pivotal-trial results, or clinical holds lifted for meaningful portfolio holdings.; Acquisitions, licensing deals, or partnerships with credible economics and upfront funding.. News that may hurt includes Failed trials, safety signals, FDA complete-response letters, or new clinical holds.; Dilutive equity offerings, short cash runway, restructuring, or programme discontinuation.. OTR also watches XBI daily holdings and equal-weight rebalance dates, FDA approval calendar, complete-response letters, and clinical holds, Clinical-trial registry status and company-reported primary endpoints.
- Next prediction
- Future calls require their own fresh entry and frozen rules. Historical context never substitutes for missing outcome evidence.
- When this can mislead
- A dramatic result may affect one small holding but barely move the ETF.; Equal-weight rebalancing can change exposure around an event.; Headline endpoints can differ from prespecified primary endpoints and safety context.; An approval can be priced in or offset by a restrictive label and weak commercial economics.
Saved headline-move memory
No source-timed headline response is available yet. OTR shows the gap instead of guessing.
Clue, not proof: timing is a clue, never proof. A price move after a headline does not prove the headline caused it. OTR uses a pattern only after it repeats and still holds up against the wider market.